Skip to content

Acorn Capital Advisors, LLC 13F Holdings · Q2 2026

Acorn Capital Advisors, LLC reported 20 securities worth $366.46M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: CGON (21.94%), URGN (16.80%), TRVI (10.92%). Among its top 25 positions this quarter: 1 new, 5 added, 3 trimmed, 3 exited.

RankTickerCompanyValue% PortfolioSharesAction
1CGONCG ONCOLOGY INC$80.4M21.94%1.1MAdded
2URGNUROGEN PHARMA LTD$61.6M16.80%1.7MHold
3TRVITREVI THERAPEUTICS INC$40.0M10.92%2.1MHold
4CADLCANDEL THERAPEUTICS INC$36.0M9.83%3.5MHold
5PBYIPUMA BIOTECHNOLOGY INC$33.5M9.14%4.1MHold
6JBIOJADE BIOSCEINCES INC$21.9M5.98%986,760Added
7BCAXBICARA THERAPEUTICS$19.1M5.21%643,381Trimmed
8KPTIKARYOPHARM THERAPEUTICS INC$14.8M4.05%1.5MAdded
9OKURONKURE THERAPEUTICS INC$12.9M3.53%2.8MHold
10HELPHELUS PHARMA INC.$10.2M2.78%1.5MHold
11TARAPROTARA THERAPEUTICS INC$6.7M1.83%1.8MHold
12AURAAURA BIOSCIENCES INC$6.6M1.80%929,077Added
13LONALEONABIO, INC.$5.8M1.59%634,539Hold
14VSTMVERASTEM INC$5.6M1.53%1.5MHold
15WHWKWHITEHAWK THERAPEUTICS INC$5.2M1.42%1.1MHold
16QTTBQ32 BIO INC.$2.8M0.75%216,171Trimmed
17ENGNEUGENE THERAPEUTICS$2.2M0.60%1.3MNew
18JSPRJASPER THERAPEUTICS$604,0270.16%1.4MAdded
19BCABBIOATLA INC$447,6450.12%108,126Trimmed
20CRDFCARDIF ONCOLOGY INC$00.00%0Exited
21TERNTERNS PHARMACEUTICALS INC$00.00%0Exited
22VYNEVYNE THERAPEUTICS INC$9260.00%1,425Hold
23XFORX4 PHARMACEUTICALS INC$00.00%0Exited

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR